Quality of Life Related to Health in Spa Users

Sponsor
University of Castilla-La Mancha (Other)
Overall Status
Unknown status
CT.gov ID
NCT03952897
Collaborator
(none)
80
1
19
4.2

Study Details

Study Description

Brief Summary

Hypothesis: The spa therapy treatment could improve health-related quality of life (HRQOL) in subjects with knee and/or hip osteoarthritis, and patients with rheumatoid arthritis.

Main objective: Analyze if HRQOL in patients with knee and/or hip osteoarthritis, and patients with rheumatoid arthritis is modified by spa therapy treatment in the spa of Fitero (Spain).

Design: Prospective observational study Participants: Fitero's spa users aged between 45-80 years old, diagnosed with knee and/or hip osteoarthritis, and also with rheumatoid arthritis. At least 40 patients of each type will be included in the study. Participants must be receiving a treatment of at least ten days.

Main Variable: The scores obtained in the Euroqol5Dimensions-5Levels questionnaire (EQ-5D-5L) (for all subjects), the Western Ontario MacMaster Universities Osteoarthritis Index (WOMAC) questionnaire, for subjects with knee and/or hip osteoarthritis, and the Health Assessment Questionnaire (HAQ), for subjects with rheumatoid arthritis.

Other variables: sociodemographic, anthropometric, clinics, and related with spa treatment.

Follow-up duration: 9 months.

Condition or Disease Intervention/Treatment Phase
  • Other: balneotherapy

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study for the Assessment of Quality of Life Related to Health in Users of the Spa of Fitero (Navarra).
Actual Study Start Date :
May 1, 2018
Actual Primary Completion Date :
Mar 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Group 1

Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.

Other: balneotherapy
10 days of balneotherapy with immersion techniques using Fitero spa water.

Outcome Measures

Primary Outcome Measures

  1. HAQ (Health Assessment Questionnaire)-Disability of rheumatic patients [From 1st March 2019 to 1st December 2019]

    Health Assessment Questionnaire (HAQ) assays the disability of rheumatic patients to carry out daily life activities. The questionary consists on 20 daily life questions, grouped in 8 areas, each one containing two or three questions related to daily life activities. Each question is scored from 0-3. 0 means "done without difficulties" (no disability), 3 score is "impossible to do" (completely disabled). The average of all responses is done. Average scores from 0-1 represent "mild to moderate difficulty", 1-2 means "moderate to severe disability", 3-2 indicates "severe to very severe disability".

  2. WOMAC [From 1st March 2019 to 1st December 2019]

    Western Ontario MacMaster Universities Osteoarthritis Index (WOMAC)

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosed arthrosis of knee or hip and/or rheumatoid arthrosis

  • balneotherapy treatment of at least 10 days.

  • physically and mentally able to complete questionnaires

Exclusion Criteria:
  • have followed a balneotherapy treatment in the six previous month

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universidad de Castilla-La Mancha Toledo Spain 45122

Sponsors and Collaborators

  • University of Castilla-La Mancha

Investigators

  • Principal Investigator: Inés Martínez-Galán, MD, University of Castilla-La Mancha

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Castilla-La Mancha
ClinicalTrials.gov Identifier:
NCT03952897
Other Study ID Numbers:
  • EO-BALNEO-19
First Posted:
May 16, 2019
Last Update Posted:
May 24, 2019
Last Verified:
May 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Castilla-La Mancha
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2019